CANCER immunotherapies, which empower patients’ immune systems to eliminate tumors, are revolutionizing cancer treatment.
Many patients respond well to these treatments, sometimes experiencing long-lasting remissions. But some cancers remain difficult to treat with immunotherapy, and expanding the impact of the approach is a high priority.
In the October 30 issue of the Proceedings of the National Academy of Sciences, a team led by Cold Spring Harbor Laboratory scientists Tobias Janowitz and Douglas Fearon together with Duncan Jodrell at the Cancer Research UK Cambridge Institute and Centre, University of Cambridge reports on a clinical trial of a drug that induces an integrated immune response in the tumors of patients with cancer types that do not usually respond to immunotherapy.
The researchers hope the potential treatment might make such tumors more responsive to the class of drugs known as immune checkpoint inhibitors.
Checkpoint inhibitors release natural brakes on the immune system
You’ve reached your free article limit
Subscribe to enjoy unlimited access to trusted journalism. Cancel anytime.
Subscribe nowNeed help? molokom@insidepolitic.co.za
